Q2 Earnings Estimate for Celcuity Issued By Leerink Partnrs

Celcuity Inc. (NASDAQ:CELC) – Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Celcuity in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will earn ($0.85) per share for the quarter. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share.

Other equities analysts have also issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Needham & Company LLC boosted their price target on Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $30.17.

Celcuity Price Performance

CELC opened at $12.59 on Friday. Celcuity has a 1 year low of $10.35 and a 1 year high of $22.19. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The company’s 50 day simple moving average is $12.31 and its 200 day simple moving average is $14.46.

Institutional Investors Weigh In On Celcuity

A number of large investors have recently modified their holdings of the stock. State Street Corp grew its position in Celcuity by 152.2% in the third quarter. State Street Corp now owns 1,107,415 shares of the company’s stock valued at $16,512,000 after acquiring an additional 668,318 shares in the last quarter. Braidwell LP boosted its stake in shares of Celcuity by 71.2% in the third quarter. Braidwell LP now owns 884,306 shares of the company’s stock valued at $13,185,000 after purchasing an additional 367,663 shares during the period. Geode Capital Management LLC grew its holdings in Celcuity by 27.6% during the 3rd quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock valued at $9,401,000 after purchasing an additional 136,518 shares in the last quarter. Candriam S.C.A. purchased a new stake in Celcuity during the 4th quarter worth $3,450,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Celcuity by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 237,706 shares of the company’s stock worth $3,112,000 after buying an additional 16,035 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.